Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series

• Published in: Revista da Sociedade Brasileira de Medicina Tropical Vol. 52; p. e20180211
• Main Authors: Arboleda, Margarita, Barrantes, Santiago, Úsuga, Luz Yaned, Robledo, Sara María
• Format: Journal Article
• Language: English
• Published: Brazil Sociedade Brasileira de Medicina Tropical - SBMT 01-01-2019; Sociedade Brasileira de Medicina Tropical (SBMT)
• Subjects: Adult; Antiprotozoal Agents - administration & dosage; Child, Preschool; Cutaneous leishmaniasis; Female; Humans; Infant; Injections, Intralesional; Intralesional meglumine antimoniate infusion; Leishmaniasis, Cutaneous - drug therapy; Male; Meglumine Antimoniate - administration & dosage; Treatment; Treatment Outcome; TROPICAL MEDICINE; Young Adult; Cutaneous leishmaniasis; Intralesional meglumine antimoniate infusion; Treatment
• ISSN: 0037-8682; 1678-9849; 1678-9849
• DOI: 10.1590/0037-8682-0211-2018

Cutaneous leishmaniasis (CL) is a high-morbidity, vector-borne disease endemic to Colombia. Unlike conventional systemic antileishmanial therapy, intralesional meglumine antimoniate administration has fewer adverse effects and can be as effective and safe. We describe 12 patients treated with intralesional meglumine antimoniate: seven with primary and five with recurrent lesions. The majority (11/12) met all cure criteria after 1-7 sessions of meglumine antimoniate administration (1-5 mL). Adverse effects comprised mainly of local pain and edema. Intralesional meglumine antimoniate administration could be an excellent alternative treatment for uncomplicated CL; however, controlled clinical trials are needed to test the efficacy and safety thereof.